All In MedTech

Device Trial Radar · NCT07390643

The DISCOVER Study

Determining ImpactS of Multi-Cancer Early detectiOn Tests oVER Time in Symptomatic Patients: The DISCOVER Study

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 11, 2026

Primary completion

Sep 24, 2026

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated device
No
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Conditions

  • Cancer
  • Cancer Diagnosis

Interventions

  • GRAIL Galleri MCED testDevice

    A multi-cancer early detection (MCED) blood test.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Multi-cancer Early Detection (MCED) Positive Cancer TypeTime frame: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
  2. Multi-cancer Early Detection (MCED) Positive Cancer IncidenceTime frame: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.
  3. Multi-cancer Early Detection (MCED) Positive Cancer StageTime frame: MCED testing will be performed at enrollment, with diagnostic resolution and cancer type determination expected within 12 months.

3 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.